Clinical and pharmacological group: & nbsp

Glucocorticosteroids

Antibiotics

Included in the formulation
  • DexaTeach
    drops d / eye 
    ROMFARMA, OOO     Russia
  • Tebridex®
    drops d / eye 
  • Tebridex®
    ointment d / eye 
  • Tebronez
    drops d / eye 
  • АТХ:

    S.01.C.A   Corticosteroids in combination with antimicrobials

    S.01.C.A.01   Dexamethasone in combination with antimicrobials

    Pharmacodynamics:

    Combined drug, in addition to dexamethasone (anti-allergic, anti-inflammatory, immunosuppressive and anti-shock) containsmichin, which has an antibacterial effect against such Gram-positive bacteria as Staphylococcus aureus, Citrobacter spp., Enterobacter spp., Staphylococcus epidermidis, and such gram-negative bacteria as Escherichia coli, Providencia spp., Proteus mirabilis, Klebsiella spp., Pseudomonas aeruginosa, Morganella morganii, Proteus vulgaris, Serratia spp.

    Tobramycin (aminoglycoside II generation) blocks the 30-S subunit of ribosomes and stops the synthesis of protein in the early stages, at higher concentrations disrupts the function of cytoplasmic membranes, causing cell death.

    Dexamethasone has glucocorticoid, anti-allergic, anti-inflammatory, immunosuppressive and anti-shock effects.

    Interaction with intracellular glucocorticoid receptors - the formation of dimers of the glucocorticoid-glucocorticoid receptor complex. Penetration of the activated receptor into the nucleus, binding to glucocorticoid-sensitive regulatory elements of DNA - a specific effect on gene expression (activation and inhibition).

    The anti-inflammatory effect of dexamethasone is due to several factors.

    1. The drug induces the synthesis of lipocortin, inhibiting the activity of phospholipase A2. Inhibition of phospholipase A mediated2 hydrolysis of membrane phospholipids of damaged tissues prevents the formation of arachidonic acid. The disruption of the formation of arachidonic acid actually means inhibition of the synthesis of prostaglandins, since arachidonic acid is a substrate for further metabolism along the cyclooxygenase pathway, and also along the lipoxygenase pathway, with appropriate inhibition of leukotriene synthesis.

    2. The anti-inflammatory effect of glucocorticoids is potentiated by their ability to inhibit the expression of COX-2 genes, which also leads to a decrease in the synthesis of prostaglandins in the inflammatory focus, including pro-inflammatory prostaglandins E2 and I2.

    3. Dexamethasone inhibits the expression of molecules of intercellular adhesion in the endothelium of blood vessels, violating the penetration of neutrophils and monocytes into the focus of inflammation. After the introduction of glucocorticoids, an increase in the concentration of neutrophils in the blood (due to their entry from the bone marrow and the restriction of migration from the blood vessels) is noted. This causes a decrease in the number of neutrophils in the site of inflammation.

    Glucocorticoids inhibit the transcription of cytokine genes that stimulate the inflammatory and immune response (IL-1, IL-2, IL-6, IL-8), as well as tumor necrosis factor (and some others). Also, a decrease in the transcription rate and an increase in the degradation of the receptor genes to IL-1 and IL-2, inhibition of transcription of the metalloproteinase (collagenase, elastase, etc.) genes involved in increasing the permeability of the vascular wall in the processes of scarring and destruction of the cartilaginous tissue in joint diseases are noted.

    Immunosuppressive effect is due to inhibition of transcription of DNA encoding the main histocompatibility complex, pro-inflammatory cytokines and inhibition of proliferation of T-lymphocytes. It leads to a decrease in the number of T-lymphocytes and their influence on B-lymphocytes, inhibits the production of immunoglobulins. Reduces formation and increases the breakdown of the components of the compliment system.

    The antiallergic effect is associated with inhibition of the synthesis of allergy mediators and inhibition of the release of mediators of allergy, and therefore it is effective in allergic reactions of immediate type.

    When applied to the surface of the skin, the drug has a rapid and pronounced effect in the inflammatory focus, reducing the severity of objective symptoms (erythema, edema, lichenification) and subjective sensations (itching, irritation, pain).

    Combination of dexamethasone with tobramycin allows to reduce the risk of infectious process.

    Pharmacokinetics:

    Systemic absorption is low, metabolized by the liver, excreted by the kidneys and through the gastrointestinal tract. The half-life is up to 54 hours.

    After topical application tobramycin absorbed through the cornea and conjunctiva. A very small amount reaches the aqueous humor of the eye. Tobramycin reaches the systemic blood flow at very low concentrations. With topical application, systemic absorption of dexamethasone is low.After instillation into the eye, it penetrates well into the epithelium of the cornea and conjunctiva, the watery moisture of the eye. Maximum activity is achieved within 10-20 minutes after application of the drug.

    The distribution of the drug was observed in blood plasma, bile, liver, kidney and renal excretion after 30 minutes from the time of admission.

    Indications:

    Conjunctivitis, blepharitis, keratitis, prevention of postoperative infectious diseases.

    VII.H00-H06.H01.0   Blepharitis

    VII.H10-H13.H10.1   Acute atopic conjunctivitis

    VII.H10-H13.H10.5   Blepharoconjunctivitis

    VII.H10-H13.H10.9   Conjunctivitis, unspecified

    VII.H15-H22.H16   Keratite

    XIX.T80-T88.T81.4   Infection associated with the procedure, not elsewhere classified

    Contraindications:

    Viral, fungal diseases of the cornea and eye tuberculosis, condition after removal of foreign body from the eye, conjunctivitis, hypersensitivity, children under 18 years of age.

    Carefully:

    Pregnancy.

    Pregnancy and lactation:

    Recommendation FDA - C. Well-controlled studies on humans have not been conducted. There is no sufficient experience in the use of the drug during pregnancy and lactation (breastfeeding).

    The use of the drug in pregnancy is possible if the expected effect of therapy for the mother exceeds the potential risk to the fetus.

    For the duration of treatment, breastfeeding should be discontinued.

    Dosing and Administration:

    Locally, 1-2 drops every 4-6 hours, with acute conditions - every hour.

    Ointment: a strip of 1.5 cm in the conjunctival sac, 3-4 times a day. You can combine the use of ointments and suspensions: ointment - in the evening before going to bed, drops - during the day.

    Side effects:

    Local allergic reactions: itching, puffiness, erythema.

    From the side of the organ of vision: increased intraocular pressure, mycosis cornea (if used consistently for 3 months), at very prolonged use may develop posterior subcapsular cataracts, secondary infection, regeneration deceleration.

    Systemic reactions: increased blood pressure, headache.

    Overdose:

    Symptoms: point keratitis, erythema, conjunctival hyperemia, increased lacrimation, and itching, swelling of the eyelids.

    Treatment: drug cancellation, eye wash with warm water and symptomatic therapy.

    Interaction:

    At simultaneous reception of steroids and aminoglycosides it is necessary to supervise their concentration in a blood.

    In the case with other ophthalmic drugs local interval between their application must be at least 10minutes.

    Special instructions:

    When used for more than 10 days, it is necessary to regularly check the intraocular pressure.

    During the treatment period, it is forbidden to wear soft contact lenses. Rigid lenses should be removed before instillation and re-put in 15-20 minutes after the procedure.

    Patients who temporarily lose visual clarity after application are advised not to drive or work with complicated equipment immediately after instillation of the drug.

    The bottle must be closed after each use. Do not touch the tip of the pipette to the eye.

    Flask-dropper with eye drops before use shake.

    Instructions
    Up